Join the Oncology Voice Network. Join for Free
Leveraging Creativity to Break into Your First MSL Role
Provide 5 keywords for SEO search separated by commas

Leveraging Creativity to Break into Your First MSL Role


Share This Article


Summary

In this episode, Alec McCarthy shares his insights on breaking into the MSL field with a creative approach. He highlights the 70/30 rule for networking, emphasizing its importance for early-career professionals, and recounts his own journey to securing an MSL position. The discussion covers strategies for effective messaging, particularly when engaging with C-suite executives, and the value of LinkedIn Premium for MSLs. Alec also explores using publishing and scientific literature to enhance job applications, aligning work with personal values, and the significance of persistence and resilience in the job search. The episode concludes with actionable advice for aspiring MSLs.

My guest today is Alec McCarthy, Medical Science Liaison at Merz Asthetics, and we discuss how to leverage creativity to break into your first MSL role.

Alec shares…

👉 What the 70/30 rule is and what the process is about
👉 What is important for aspiring MSLs to get noticed
👉 How to approach companies that you are targeting
👉 What tools and resources to rely on during the search process
👉 Creative tips

Click for Source
Provide 5 keywords for SEO search separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Start a Diversity Equity & Inclusion Program in Pharma
Partner Avatar MSL Talk: Tom Caravela, Tara Gonzalez

How to Start a Diversity Equity & Inclusion Program in Pharma

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Article
Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials
OVN Avatar Shubham Sharma, J Connor Wells, Wilma M Hopman, Joseph C Del Paggio, Bishal Gyawali, Nazik Hammad, Annette E Hay, Christopher M Booth

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Explore OVN